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Abstract
 
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a peculiar T cell lym-
phoma, as expanding B cell clones are often present besides the malignant T cell clones. In ad-
dition, large numbers of Epstein-Barr virus (EBV)-infected B cells are frequently observed. To
analyze the differentiation status and clonal composition of EBV-harboring B cells in AILD,
single EBV-infected cells were micromanipulated from lymph nodes of six patients with fre-
quent EBV
 
 
 
 cells and their rearranged immunoglobulin (Ig) genes analyzed. Most EBV-
infected B cells carried mutated Ig genes, indicating that in AILD, EBV preferentially resides in
memory and/or germinal center B cells. EBV
 
 
 
 B cell clones observed in all six cases ranged
from small polyclonal to large monoclonal expansions and often showed ongoing somatic hy-
permutation while EBV
 
 
 
 B cells showed little tendency for clonal expansion. Surprisingly,
many members of expanding B cell clones had acquired destructive mutations in originally
functional V gene rearrangements and showed an unfavorable high load of replacement muta-
tions in the framework regions, indicating that they accumulated mutations over repeated
rounds of mutation and division while not being selected through their antigen receptor. This
sustained selection-free accumulation of somatic mutations is unique to AILD. Moreover, the
survival and clonal expansion of “forbidden” (i.e., Ig-deficient) B cells has not been observed
before in vivo and thus represents a novel type of viral latency in the B cell compartment. It is
likely the interplay between the microenvironment in AILD lymph nodes and the viral trans-
formation that leads to the survival and clonal expansion of Ig-less B cells.
Key words: B lymphocytes • somatic hypermutation • EBV • immunoglobulin genes • 
single cell PCR
gressive course. Affected patients suffer from generalized
lymph node swelling, fever, rash, and predisposition to in-
fections. Histologically, affected lymph nodes show an ef-
faced structure, usually with disappearance of follicles and
germinal centers (GCs) but presence of a diffuse network of
follicular dendritic cells (FDCs), proliferation of venules
and an infiltrate of polymorphous atypical T cells and also
B immunoblasts (1).
In most cases of AILD, clonal expansion of T cells can be
detected using Southern blot analysis or PCR strategies (2–
5). In a proportion of cases also clonal expansion of B cells
was demonstrated, and different expanded B cell clones
were observed in sequential biopsies (6–8). Furthermore,
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Abbreviations used in this paper:
 
 AILD, angioimmunoblastic lymphaden-
opathy with dysproteinemia; EBNA, EBV nuclear antigen; EBV, Epstein-
Barr virus; FDC, follicular dendritic cell; GC, germinal center; HHV, hu-
man herpes virus; HL, Hodgkin’s lymphoma; HRS, Hodgkin–Reed/
Sternberg; LMP, latent membrane protein; RT, reverse transcription.
 
Introduction
 
Angioimmunoblastic lymphadenopathy with dysproteine-
mia (AILD)
 
*
 
 represents one of the most frequent T cell
lymphomas in the Western world and usually takes an ag- 
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diffuse large B cell lymphomas occasionally develop in
AILD patients (9–11).
Epstein-Barr virus (EBV), a human herpes virus infecting
 
 
 
90% of adults, has been detected by in situ hybridization in
B cells of 80–95% of AILD-involved lymph nodes and in
some cases also in T cells (8, 12, 13). Whereas in healthy
EBV carriers, EBV resides in B cells at a frequency of 
 
 
 
1 in
10
 
5
 
–10
 
6
 
 
 
(14, 15), in lymph nodes of AILD patients 1 in 10
to 1 in 500 B cells may be EBV-infected
 
 
 
(12, 13; see below).
EBV is also associated with a variety of other lympho-
mas. More than 95% of endemic Burkitt’s lymphoma and
 
 
 
40% of classical Hodgkin’s lymphoma (HL) show EBV
infection of the tumor cells (16). Furthermore, during states
of immunosuppression as in HIV-infected patients or in
patients after organ transplantation, EBV
 
 
 
 high grade B cell
lymphomas are observed at increased frequency (17, 18).
The lymphomas differ in the pattern of EBV latent gene
expression. Only the EBV nuclear antigen (EBNA)1 is ex-
pressed in Burkitt’s lymphoma, Hodgkin–Reed/Sternberg
(HRS) cells of HL show in addition expression of the latent
membrane proteins (LMPs) 1 and 2a, and lymphomas in
immunodeficient states show expression of all nine latent
proteins (16). In healthy carriers, EBV is found in a latent
form in resting memory B cells in the peripheral blood, and
the virus-infected cells lack expression of most, if not all,
latent proteins (19). These cells are tightly controlled by vi-
rus-specific T cells (20, 21).
The role of EBV and the origin and state of maturation
of EBV-infected B cells in AILD are unknown. Here, we
analyzed the Ig gene rearrangements of single EBV-infected
cells micromanipulated from frozen tissue sections of
six cases of AILD with a relatively high content of EBV-
infected cells in order to define their clonal composition
and stage of differentiation. In addition, from one of the
six cases and three further cases with no or few EBV
 
 
 
 cells,
single EBV
 
 
 
 B cells were analyzed for comparison.
 
Materials and Methods
 
Tissues and Clinical Data.
 
Frozen biopsies taken for diagnostic
purposes were from the Departments of Pathology of the Univer-
sities of Kiel and Henri Mondor. The six cases used for analysis of
EBV-infected B cells were selected from 20 cases for their rela-
tively high content of EBER
 
 
 
 cells (Fig. 1). Clinical data for the
patients are summarized in Table I. All cases were examined by at
least two experienced hematopathologists.
 
Immunostaining, EBER In Situ Hybridization, and Double Stain-
ing for EBER and CD20.
 
Immunostaining was performed on
5–8-
 
 
 
m thick paraffin sections using monoclonal antibodies
against CD20, LMP1, BZLF1, and EBNA2 (all from Dako). For
antigen retrieval, deparaffinated and rehydrated sections were
subjected to 2 min of high pressure cooking in citrate buffer, pH
6. Specifically bound primary antibodies were detected using bio-
tinylated secondary antibodies (Dako) and avidin-coupled alka-
line phosphatase (Dako). Fast Red or BCIP/NBT (Dako) served
as substrate for alkaline phosphatase.
Frozen tissue sections were used for Ki67 (polyclonal; Dako),
CD20 and Ki67/CD20 double stainings. For the double stain-
ings, horseradish peroxidase–coupled goat anti–rabbit and alkaline
phosphatase–coupled goat anti–mouse antibodies were used with
diaminobenzidine and Fast Red as substrates.
EBER in situ hybridization for detection of EBV-infected cells
was carried out on paraffin and frozen sections using digoxigenin-
labeled EBER1 and EBER2 probes as described previously (22).
Plasmids for generation of probes were provided by G.
Niedobitek, Department of Pathology, Friedrich-Alexander Uni-
versity, Erlangen, Germany. Double staining for CD20 and
EBER was performed on frozen tissue sections. Before in situ hy-
bridization, sections were incubated with peroxidase-coupled
anti-CD20 antibody (CD20-EPOS; Dako) and visualized with
Diaminobenzidine (Sigma-Aldrich) as chromogen. In situ hy-
bridization was continued as described previously.
 
Fragment Length Analysis.
 
DNA was extracted from eight to
ten 10-
 
 
 
m sections of frozen tissues using a silica column system
(QiaAmp; Qiagen). TCR-
 
 
 
 rearrangements were amplified in
two separate reactions with the consensus primers V
 
1–8
 
 and V
 
9–11
 
and the same set of three Fam2-labeled J primers in both reac-
tions (23). PCR products were analyzed with an automatic se-
quencer (ABI377; Applied Biosystems) and the GeneScan soft-
ware.
 
Detection of Human Herpes Virus 8 in DNA from Whole Tissue
Sections.
 
30–60 ng of DNA from frozen tissues (see Fragment
Length Analysis) (equivalent to 0.6–1.2 
 
  
 
10
 
4
 
 cells) were used in
a seminested PCR to amplify a 230-bp fragment of the ORF26
of human herpes virus (HHV)8. Both PCRs were performed in
1
 
 
 
 PCR buffer (Boehringer) with 2 mM dNTPs (Amersham
Pharmacia Biotech), 0.125 
 
 
 
M for each primer and 2.5 and 2.0
mM MgCl
 
2
 
 for the first and second round, respectively. In the
first round HHV8US1 and HHV8LS1 were used, in the second
round HHV8US1 together with HHV8LS2 (HHV8US1: 5
 
 
 
-
GAAAGGATTCCACCATTGTGCTCG-3
 
 
 
; HHV8LS1: 5
 
 
 
-
ATGGACAGATCGTCAAGCACTCGC-3
 
 
 
; HHV8LS2: 5
 
 
 
-
CCGTGTTGTCTACGTCCAGACG-3
 
 
 
). After an initial cycle
with 5 min at 95
 
 
 
C, 4 min at 65
 
 
 
C when the enzyme was added,
and 1 min at 72
 
 
 
C, 39 cycles with 30 s at 95
 
 
 
C, 30 s at 61
 
 
 
C and
45 s at 72
 
 
 
C were performed in the first round of PCR. Cycle
conditions for the second round of PCR were the same as for the
first round, except that the initial denaturation at 95
 
 
 
C was re-
duced to 2 min. With this seminested PCR, HHV8 DNA could
be detected in 60 pg of DNA (equivalent to 
 
 
 
12 cells) extracted
from a HHV8-positive Kaposi sarcoma.
 
Micromanipulation and Single Cell PCR.
 
Single EBER
 
 
 
, CD20
 
 
 
,
EBER
 
 
 
/CD20
 
 
 
, Ki67
 
 
 
, and Ki67
 
 
 
/CD20
 
 
 
 cells were micro-
manipulated with a hydraulic micromanipulator from 5-
 
 
 
m sec-
tions of frozen tissues covered with buffer and transferred to 20 
 
 
 
l
PCR buffer in PCR tubes as described previously (24, 25). Dur-
ing all micromanipulation procedures aliquots of buffer covering
the sections were taken as negative controls, usually four buffer
aliquots for each 10 micromanipulated cells. After 2 h of protein-
ase K digestion, rearranged IgH, Ig
 
 
 
, and Ig
 
 
 
 genes and a frag-
ment of the EBNA1 gene were amplified by seminested PCR as
described previously (25–28). In the first round of PCR, family-
specific primers for the framework region I of the IgH, Ig
 
 
 
, and
Ig
 
 
 
 V gene segments were used together with sets of primers for
the corresponding J segments and EBNA1-specific primers. For
cases 4–6, in addition, family-specific D
 
H
 
 primers binding 100–
200-bp 5
 
  
 
of the D
 
H
 
 segments were used together with the IgH
primer set. In second round PCRs the same family-specific V
primers (and for cases 4–6 also the family-specific D
 
H
 
 primers)
were used in separate PCRs for each V (or D
 
H
 
) gene family to-
gether with nested J primers. PCR products were gel-purified
and directly sequenced. 
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For case 5, 20 EBER-ISH
 
 
 
 cells were also analyzed for
HHV8. In the first round of PCR, conditions were as described
for the V gene rearrangement and EBNA1 PCR. The IgH- and
EBNA1-specific primers were used together with HHV8US1 and
HHV8LS1, each of the latter at 0.05 
 
 
 
M. In a separate second
round for HHV8, HHV8US1 and HHV8LS2 primers were used
for 40 cycles (for PCR conditions see Detection of HHV8 in
DNA Extracted from Whole Tissue Sections). 10 single cells from
a HHV8-positive cell line (CRO AP2; reference 29) served as
positive control, and HHV8 was detected in 8 of 10 of these cells.
 
Reverse Transcription PCR.
 
RNA was isolated from 10–25
mg of frozen tissues (
 
 
 
2–5 
 
  
 
10
 
6
 
 cells, high pure tissue RNA
isolation kit; Boehringer). One-tenth of the RNAs were used for
cDNA synthesis with random hexamers and AMV reverse tran-
scriptase (1st strand cDNA synthesis kit for reverse transcription
(RT)-PCR; Boehringer). The isolation of amplifiable RNA was
tested with primers for 
 
 
 
-actin (
 
 
 
-actinUS: 5
 
 
 
-CACCTTCTA-
CAATGAGCTGCGTG-3
 
 
 
 and 
 
 
 
-actinLSa: 5
 
 
 
-GGCGTA-
CAGGGATAGCACAGC-3
 
 
 
; a 170-bp product from cDNA
and a 610-bp product from genomic DNA), each 0.125 
 
 
 
M, in
1
 
  
 
PCR buffer (Boehringer) with 2 mM dNTPs and 2 mM
MgCl
 
2
 
 and 1/100 of the cDNA as template in a PCR with an
initial cycle of 2 min at 95
 
 
 
C, 4 min at 65
 
 
 
C, and 1 min at 72
 
 
 
C,
followed by 24 cycles with 30 s at 95
 
 
 
C, 30 s at 61
 
 
 
C, and 45 s at
Figure 1. EBER in situ hybrid-
ization for two cases of AILD.
EBER in situ hybridization was per-
formed on paraffin sections as de-
scribed in Materials and Methods. 
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72
 
 
 
C. PCR products from all cases were sequenced to exclude
the amplification of processed 
 
 
 
-actin pseudogenes.
1/10 of the cDNAs served as templates for detection of
LMP2a transcripts in a seminested PCR. In the first round
LMP2aF1 and LMP2aRa were used, each 0.125 
 
 
 
M, in 1
 
 
 
PCR buffer (Boehringer) with 2 mM dNTPs and 2 mM MgCl
 
2
 
.
Cycle conditions were 2 min at 95
 
 
 
C, 4 min at 65
 
 
 
C, and 1 min
at 72
 
o
 
C followed by 39 cycles with 30 s 95
 
 
 
C, 30 s 61
 
 
 
C, and 45 s
72
 
 
 
C. 1 
 
 
 
l aliquots of the first rounds were used as templates in
second rounds with the same PCR conditions as in the first
round, except the usage of LMP2aF1 together with LMP2aRi
and an annealing temperature of 57
 
 
 
C (LMP2aF1: 5
 
 
 
-TCTCAA-
CACATATACGAAGAAGCG-3
 
 
 
; LMP2aRa: 5
 
 
 
-GCGGTCA-
CAACGGTACTAACTG-3
 
 
 
; LMP2aRi: 5
 
 
 
-AACTGAGGC-
CGTGAAACACGAG-3
 
 
 
; a 123-bp product from cDNA and a
 
 
 
5,000-bp product from genomic DNA).
 
Results
 
Immunohistology, EBER In Situ Hybridization, RT-PCR,
and TCR-
 
  Fragment Length Analysis. All selected cases
displayed the typical histological and immunohistological
picture of AILD, i.e., proliferation of (partly atypical)
CD3  T cells, admixed with scattered CD20  B immuno-
blasts and hyperplastic FDC networks. By EBER in situ
hybridization, which detects all virus-harboring B cells,
moderate to high amounts of EBV-positive cells were ob-
served in six cases from which EBV-infected cells were mi-
cromanipulated (Fig. 1), while in three other cases no or
few EBV-infected cells were detected (Table I). Immuno-
histology for BZLF1 (whose expression indicates that cells
switched from latent to lytic infection (30, 31)) and
EBNA2 (typical for cells expressing all latent EBV proteins)
was negative in all cases analyzed. Scattered LMP1  cells
were observed in cases 2 and 4. In case 5, LMP1-positive
cells accounted for about one- third of the EBER-positive
cells, partly displayed the morphology of large blasts and
were predominantly arranged in a nodular fashion through-
out the lymph node. As LMP2a immunostainings could
not be evaluated because of unspecific staining, RT-PCR
of RNA isolated from whole tissue sections of cases 1–6
was used to detect LMP2a expression. Cases 4, 5, and 6
tested positive (Table I).
In a fraction of AILD cases, another human herpes vi-
rus, HHV8, associated with B cell malignancies and with
transforming potential in animal models, has been de-
tected (32–34). In a sensitive seminested PCR with DNA
from cases 1–6, HHV8 DNA was detected only in case 5
(data not shown). However, when single EBV-infected
cells from this same case were analyzed, no coinfection of
EBV-positive cells with HHV8 was observed (see Materi-
als and Methods). Therefore, the features of the EBV-
infected B cells analyzed in this study and described below
are not influenced by a coinfection of the cells with
HHV8.
To analyze the cases for the presence of clonal T cell
populations, a PCR amplification of TCR-  gene rear-
rangements from DNA extracted from whole tissue sec-
tions and subsequent determination of length and intensity
distributions of the fluorescent-labeled PCR products was
performed (23, 35). This approach is suitable to detect
clonal expansions among TCR-  – as well as TCR-  –
expressing T cells, since also the latter usually carry TCR- 
gene rearrangements. In all four of the six EBV-rich cases
informative for TCR-  rearrangements (cases 1, 2, 4, and
5; in cases 3 and 6 signals were too low for evaluation; Ta-
ble I), the results were indicative of a single T cell expan-
sion in each patient, thus supporting the diagnosis of T cell
lymphoma at the molecular level. Among the three cases
used for analysis of EBV-negative B cells only in case 9 a
dominant T cell clone was detected.
Table I. Description of Nine Cases of AILD
Case Sex Age
Lymph node
biopsy site
Percentage
CD20  cells
Percentage
EBER  B cellsa EBNA1 LMP1 LMP2a EBNA2 BZLF1
TCR- 
length distribution
1 M 72 Cervical 20 0.1–1        1 clone, polyclonal backgroundb
2 F 81 Cervical 10 1–10 ND        1 clone, polyclonal backgroundb
3 F 77 Cervical 20 0.1–1   ND   ND ND NE
4 M 86 Axillary 5 1–10        monoclonal
5 M 37 Inguinal 20  50        monoclonal
6 F 70 Supraclavicular 25 1–10   NE     NE
7 M 58 Inguinal 25 0 ND ND ND ND ND polyclonal
8 F 43 Axillary 20  0.01 ND ND ND ND ND polyclonal
9 F 73 Axillary 15  0.1 ND ND ND ND ND monoclonal
CD20, EBNA1, LMP1, EBNA2, and BZLF1 expression were determined by immunohistochemistry; LMP2a expression by RT-PCR.
aGiven is the percentage of EBER+ B cells among B cells, assuming that all EBER  cells are B cells. For cases 5 and 6 also single micromanipulated
CD20+ cells were tested for EBV infection in an EBNA1-specific PCR. 80 and 20% of the B cells were EBNA1 , respectively.
bBesides a dominant peak, showing presence of a large (tumor) clone, smaller signals of various length in a Gaussian type distribution were visible, in-
dicating presence of polyclonal T cells in addition to the large clone. The signals for the TCR-  PCR of cases 3 and 6 were too low for evaluation.
NE, not evaluable.931 Bräuninger et al.
Clonal Expansion among EBER  and CD20  Cells. Be-
tween 50 and 115 single EBER  cells were micromanipu-
lated from frozen tissue sections of six EBV-rich cases (Ta-
ble II). All cells were subjected to seminested PCR for
rearrangements at the IgH, Ig , and Ig  loci and in most
instances also tested for EBV-infection in an EBNA1-spe-
cific PCR. From 31 to 58% of the micromanipulated cells
at least one Ig gene rearrangement was obtained, and be-
tween 24 and 125 Ig rearrangements were amplified per
case. Comparison of the Ig gene sequences identified clonal
expansions among the EBV  cells in all six cases (Table II).
However, the number of clones and the extent of clonal
expansion differed markedly between cases. In patients 1–3,
60–90% of the EBER  cells could be assigned to several
clones of varying sizes (case 1: 10 clones with 2–7 mem-
bers; case 2: seven clones with 2–18 members; and case 3:
six clones composed of 2–4 cells). In case 4, a dominant
clone encompassing nearly half of the EBER  cells was
Table II. PCR and Sequence Analysis of Rearranged Ig Genes of Single EBER  and CD20  Cells of AILD
Case Cells
Cells positive/
cells analyzeda
Cells with mutated rearrangements/
cells informativeb
Cells assigned
to clones
Unique
cells
Number
of clones
Cells
per clone
Clones with
intraclonal diversity
%%
EBV 
1 EBER  59/103 56/56 (100) 37 (63) 22 10 2–7 3c
2 EBER  53/115 50/50 (100) 47 (89) 6 7 2–18 6
3 EBER  26/56 13/23 (57) 15 (58) 11d 6d 2–4 2c
4 EBER  48/101 44/44 (100) 26 (54) 22 3 2 2, 22 1
5 EBER  21/70 21/21 (100) 21 (100) 0 1 21 1
6 EBER  27/50 25/25 (100) 27 (100) 0 1 27 1
EBV / 
5 CD20  14/40 EBNA  13/14 (93) 12 (86) 2 1e 12 1
3/40 EBNA  3/3 (100) 0 3 0 0 0
6 CD20  4/56 EBNA  3/3 (100) 4 (100) 0 1e 41
17/56 EBNA  13/15 (87) 14 (82) 3 1e 14 1
EBV 
2
EBER 
/CD20  24/49f 13/42 (31)f 42 0 2 g 2 20
7 Ki67  18/106h 11/17 (65) 11 (61) 7 1 11 1
8 Ki67  26/140 5/19 (26) 0 26 0 0 0
9 CD20  88/300h 60/81 (74) 2 86 1 2 0
PCR for DH/JH rearrangements was performed for cases 4, 5, and 6. For the large clone of case 4 a clonal DH6–25/JH2 rearrangement was coamplified
with the clonal VH or V  rearrangement from 8 of 22 cells, for case 5 a clonal DH3–9/JH6 rearrangement was coamplified with the clonal VH
rearrangement from 6 of 20 cells analyzed and for case 6 a clonal DH3–9/JH5 rearrangement was coamplified with the clonal VH rearrangement from
5 of 20 cells analyzed. All sequences have been deposited at the EMBL database under AJ347089-703 and AJ344348-350.
In all micromanipulation experiments aliquots of buffer covering the sections were aspirated as negative controls (usually four buffer aliquots for each
10 cells). For case 1, from 1 of 42 buffer controls a VH rearrangement also amplified from a cell belonging to a clone, and from another buffer aliquot
three unique VH rearrangements were amplified. For case 4, a unique VH rearrangement was amplified from one of 41 buffer controls and from two
of 43 buffer controls for case 6 the clonal VH rearrangement was amplified. For case 9 the same VH rearrangement was amplified from three buffer
controls. This rearrangement was unrelated to any other rearrangement amplified in this study.
aIf not stated otherwise, “cells positive” refers to cells positive for both Ig gene rearrangements and a fragment of the EBNA1 gene. Some rare
EBER+ cells for which only Ig or EBNA1 amplificates were obtained are not considered. In case 4, 22 Ig-positive cells of 30 cells analyzed without
the EBNA1 PCR are included. No EBNA1 PCR was performed for all EBER+ cells of case 6.
bCells from which only unmutated V  rearrangements were amplified are not considered for the mutation analysis, since such joints are not informa-
tive for mutation analysis (reference 41).
cOne clone of cases 1 and 3 each were not informative regarding intraclonal diversity as the clonal rearrangements amplified several times were un-
mutated out-of-frame V  rearrangements.
dIn case 3, two of ten informative cells among the 11 unique cells carried unmutated rearrangements, and also three of six clones were unmutated.
eThe same clone as the one identified among the EBER+ cells of the respective cases.
fIn this experiment groups of 2–3 cells were analyzed in one PCR tube. Consequently, the number of mutated rearrangements/informative rear-
rangements is given.
gOne clone with mutated, the other clone with unmutated Ig gene rearrangements.
hFive Ig+ cells belonging to the clone of case 7 and 17 Ig+ cells of case 9 were tested for EBNA1. All cells were negative. In case 9, 17 cells from
which rearrangements were amplified, were micromanipulated as CD20+/Ki67+ cells.932 Ig-deficient B Cells in Angioimmunoblastic T Cell Lymphoma
Figure 2. Genealogical trees for examples of clonal expansions of EBV-infected B cells and an EBV-negative clone (case 7) with ongoing somatic hy-
permutation from six cases of AILD. Genealogical trees are based on alignments obtained with the GeneWorks software 2.5 (Intelligenetics) and only
shown for originally potentially functional rearrangements. Presumed precursors are boxed. Assumed intermediates are included in the genealogical trees
and marked as X. Inactivating mutations are shown within the circles (for rearrangements which acquired sequentially inactivating mutations only the
initially inactivating ones are shown). For clone 2 of case 2, several pairs of rearrangements each with one shared mutation were observed, but together
were partly incompatible regarding the construction of a genealogical tree. Therefore, a fraction of these shared mutations was likely due to independent
mutation events. For three of such mutations a single mutation event was assumed (no mutation hot spot in the RGYW motif and no other mutations at
the same position). In cases 1, 2, and 3 circles mostly represent single cells. If identical rearrangements were obtained from several cells, this is indicated
below the circles. In cases 4, 5, and 6 the circles usually represent several cells with ongoing somatic hypermutation. Numbers of cells and variants iden-
tified are given beside the circles. In case 6 the EBV  cells were micromanipulated using a CD20 staining and subsequently tested in an EBNA1-PCR.
The 21 EBV  cells of one subclone are composed of 19 EBER-ISH  cells and two cells tested positive for EBNA1, the eight EBV  cells of a second
subclone are composed of six EBER-ISH  cells and two EBNA1  cells. In case 7, one cell could not be fit in the genealogical tree, because VH and V 
rearrangements would belong to different branches. These rearrangements may represent cellular contaminations during the micromanipulation proce-
dure. aa, amino acid; del, deletion; mut, mutation.933 Bräuninger et al.
identified. In cases 5 and 6, all EBER  cells belonged to a
single clone.
To analyze whether the large clonal expansions of cases 5
and 6 were restricted to EBV-positive cells and/or ac-
counted for most B cells in the tissue, for both cases also
CD20  cells were micromanipulated and tested for infec-
tion with EBV in an EBNA1-specific PCR (Table II). In
case 5, 14 of 17 CD20  cells were positive for EBNA1.
Thus, in this case  80% of the CD20  B cells are EBV-
infected. Furthermore, nearly all EBV-positive cells of this
case (33 of 35 cells taking EBER  and CD20 /EBNA1 
cells together) belonged to one clone. The three EBNA1
PCR-negative cells carried unique rearrangements. In con-
trast to case 5, in case 6 only a small fraction of the CD20 
cells was EBV-infected (4 of 21 Ig-PCR positive cells were
also positive in the EBNA1-PCR). The four EBV-positive
cells belonged to the same clone identified among the
EBER  cells. Surprisingly, also 14 of 17 CD20  and
EBNA1 PCR-negative cells could be assigned to this clone.
Since the EBNA1-specific PCR works very efficiently and
since 9 of the EBNA1-PCR-negative cells define a distinct
subclone in the genealogical tree of this clone (Fig. 2), we
conclude that in this case, the B cell population consisted
largely of a single dominant clone and only about a quarter
of the cells in this clone are EBV-infected, perhaps due to a
single infectious event in the history of the clone.
Some CD20 /EBER  B cells were also micromanipu-
lated from case 2 to analyze the clonal composition and dif-
ferentiation status of EBV-negative B cells. Among the 42
rearrangements amplified from 24 EBER  and EBNA1
Figure 2 (continued)934 Ig-deficient B Cells in Angioimmunoblastic T Cell Lymphoma
PCR-negative samples (two to three cells were analyzed
together in each PCR) none was clonally related to those
amplified from EBER  cells. Only two pairs of clonally re-
lated cells were identified.
In addition, for a comprehensive comparison of EBV 
and EBV  B cells in AILD, from three further cases with
no or few EBV  cells, single proliferating (Ki67 ) cells, B
cells (CD20 ) and proliferating B cells (Ki67 /CD20 )
were micromanipulated (Ki67 staining was chosen because
the analysis of these cases was originally focused on prolif-
erating B cells in EBV  cases of AILD). In case 8, no
clonally related B cells were identified and in case 9, only 2
of 71 informative cells were clonally related. A single
EBV  B cell clone encompassing nearly 2/3 of the prolif-
erating B cells was identified in case 7. As in this case no T
cell clone was detected, this B cell clone may represent a B
cell tumor that developed in the background of AILD as
described previously (9–11).
Taken together, in each of the six EBV-rich cases clonal
B cell expansions were detected among the EBV-infected
cells, ranging from polyclonal populations with several
small clones to monoclonal expansions dominating the B
cell population in the tissue. One case with a large mono-
clonal expansion included EBV  as well as EBV  B cells.
With the exception of one large clone in an EBV  case,
EBV  B cells showed little tendency for clonal expansion.
Somatic Mutation in Rearranged Ig Genes of EBV-infected B
Cells. Rearranged Ig genes of EBV-infected B cells were
evaluated for the presence of somatic mutations, consider-
ing members of clones and EBV-harboring cells not as-
signed to clones (unique cells) separately. Analysis of the se-
quences amplified from unique EBV-infected cells revealed
that 55 of 58 informative cells from cases 1–5 carried mu-
tated V genes. The average mutation frequency of 5.4% for
VH rearrangements (n   29; range 0.4–11.9%) is within the
range typical for memory B cells (36).
Among the EBV-infected cells belonging to expanded
clones, three types of clonal expansions were identified
based on the presence and pattern of somatic mutation
(two clones are not considered, see legend to Table II): (i)
only three of the 26 clones carried unmutated V region
genes. These three clones were all identified in case 3 and
consisted of only 2–4 members. (ii) Nine clones identified
in cases 1, 2, and 4 had mutated V genes with an average
mutation frequency of 7% for VH rearrangements (n   8,
range 3.5–11.6%) but did not show intraclonal diversity.
Most of these nine clones were small and defined by only
two members. (iii) In 14 clones with mutated V genes in-
traclonal diversity was observed (Table II and Fig. 2). Such
clones were identified in all six cases. The extent of intra-
clonal diversity varied considerably between the clones,
ranging from three sequence variants among 17 sequences
(clone 1 of case 4) to 12 variants among 15 sequences
(clone 2 of case 2). Also the numbers of shared mutations
differed markedly between clones. For the dominant clones
of cases 4–6 several shared mutations were identified,
whereas for clones 1 and 2 of case 2 no mutations common
to all clone members were observed (Fig. 2). The average
mutation frequency of VH rearrangements for clones with
ongoing mutation from cases 1–4 was 2.8% (identical mu-
tated rearrangements were counted only once; n    35,
range 0–7.2%), and for the two clones of cases 5 and 6 the
least mutated members showed 10 and 17% mutation fre-
quency, respectively.
The clone detected among EBV  cells in case 7 showed
also intraclonal diversity besides 20 and 33 shared mutations
in its VH and V  rearrangements, respectively (Fig. 2).
Taken together, the vast majority of EBV-infected B
cells carried somatically mutated V region genes, and many
members of EBV  B cell clones showed ongoing hyper-
mutation, indicating that the virus preferentially resides in
GC and perhaps also memory B cells.
Frequent Crippling Somatic Mutations in Clonally Expanding
EBV-infected B Cells. Surprisingly, the analysis of the mu-
tation pattern disclosed a large number of crippling muta-
tions in originally potentially functional V gene rearrange-
ments. These destructive mutations were either nonsense
mutations or duplications or deletions resulting in loss of
the correct reading frame. Most destructive mutations were
found in clones showing ongoing somatic mutation (Table
III). For each of the large clones of cases 4–6, inactivating
mutations were found in the in-frame V gene rearrange-
ments (Fig. 2). In cases 5 and 6, amplification of DHJH rear-
rangements from the second IgH alleles confirmed that the
inactivated VHDHJH rearrangements were indeed the origi-
nally functional ones (see legend to Table II). The 11 cells
belonging to the EBV  clone of case 7 carried various dif-
ferent mutations rendering either the originally potentially
functional VH or the functional V  rearrangement nonfunc-
tional, while none of the shared mutations was crippling
(Fig. 2).
Nonsense mutations were found in originally potentially
functional rearrangements of clones with ongoing mutation
with an average frequency of 7.7% of all mutations (or 6.5%
if, to estimate the frequency of destructive nonsense muta-
tions, in V genes with several nonsense mutations only one
is counted). This contrasts with the 0% (0 in 143 mutations)
and 0.2% (1 in 515 mutations) nonsense mutations found in
clones without ongoing mutation and unique cells, respec-
tively (Table III). For mutations that a priori could not be
subject to selection (i.e., mutations in out-of-frame rear-
rangements and mutations that occurred in already clonally
inactivated rearrangements), a frequency of 5.2% nonsense
mutations was observed, which is close to the calculated
theoretical value of 4.7% assuming random mutagenesis
without selection (37). Thus, the originally functional V
genes of clones with ongoing mutations accumulated non-
sense mutations with a frequency somewhat higher than in
the case of nonproductive, nonselected rearrangements.
In normal GC B cells, deletions or duplications account
for  6% of somatic mutation events, as has been calculated
from their frequency in mutated out-of-frame rearrange-
ments (38). In this study, the frequency of deletions/dupli-
cations in nonproductive rearrangements was somewhat
lower (3.5%). In functional V region genes most deletions/
duplications result in loss of the correct reading frame or935 Bräuninger et al.
cripple a V gene rearrangement because a large part of the
rearrangement is lost or duplicated. Such deletions/dupli-
cations are therefore stringently counterselected, so that ex-
pressed V genes of post GC B cells only rarely carry such
mutations (usually 3- or 6-bp deletions/duplications in the
complementary determining regions). In line with this,
deletions/duplications were only rarely observed in the
present study in in-frame rearrangements of clones without
ongoing mutation and in unique rearrangements, with fre-
quencies of 0.7 and 0.6%, respectively (Table III). How-
ever, in originally functional rearrangements of clones with
ongoing mutation, deletions and duplications were found
with a frequency of 6.4%, and many of those were destruc-
tive, further indicating that these rearrangements acquired
somatic mutations without selection for functionality.
In addition to the counterselection of destructive muta-
tions, also the ratio of replacement (R) to silent (S) muta-
tions in FRs of functional Ig gene rearrangements is indica-
tive for selective pressure on a cell to express a functional
antigen receptor. In cells selected for expression of a
functional B cell receptor, R mutations in FRs are usu-
ally counterselected. Thus, for selected memory B cells a
R/S ratio of 1.0 to 1.6 is usually observed, contrasting
with the ratio of   3.0 for V gene rearrangements that
acquire somatic mutations without selection, like out-
of-frame rearrangements (Table III). The out-of-frame
rearrangements analyzed in this study showed an average
R/S value of 2.5. For the in-frame rearrangements of
clones without ongoing mutation and the unique
EBER  cells, we observed R/S ratios of 1.1 and 1.3, re-
spectively, indicative of stringent selection for expres-
sion of a functional antigen receptor, like in normal B
cells. In contrast, the R/S ratio for clones with intra-
clonal diversity is 2.7, and thus similar to that of rear-
rangements that acquire mutations without selection for
functionality.
Taken together, each of the three features of somatic hy-
permutation analyzed (the frequency of nonsense muta-
tions, the frequency of deletions/duplications, and the R/S
ratios) indicate that expanding EBV-infected B cells in
Table III. Somatic Mutation Pattern of Ig Gene Rearrangements from EBER  Cells of AILD
Deletions and duplicationsb
Rearrangements
No. of
rearrangements 
analyzed
Frequency 
of nonsense
mutationsa
Percentage of
all mutations
Total
(No.)
Destructive
(No.)
Replacement/silent mutations 
in framework regions
%
Potentially functional
Unique cells (n   39) 55 0.2 (1/515) 0.6 3 2 1.3 (143/110)
Clones without ongoing mutation
(n   8)
12 0.0 (0/143) 0.7 1 0 1.1 (36/33)
Clones with
ongoing mutationc (n   12)
78 6.5(16/247)d
7.7 (19/247)
6.4 17e 11 2.7 (70/26)
Memory B cellsf   0.0 0.2    1.0–1.6
Nonfunctional
This studyg 151 5.2 (27/522) 3.5 19 14 2.5 (190/75)
Literatureh   4.8 6.0 20 20 3.0
For clones only Ig gene rearrangements amplified at least two times are considered.
aShared mutations counted only once.
bEight of nine insertions represent duplications.
cFor the dominant clones of cases 4 and 5 only the shared mutations are considered, as these rearrangements are inactivated by clonal mutations.
Case 6 is not considered, as in this case most likely a subclone of an EBV-negative transformed B cell clone with clonal inactivated VH rearrange-
ment was EBV infected.
dCounting for rearrangements with several nonsense mutations only one for each rearrangement (6.5%) or all (7.7%).
eThree of the “nondestructive” (i.e. preserving the correct reading frame) deletions/duplications were an 18-bp deletion at the end of a CDRIII, an
18-bp duplication in a CDRI and a 33-bp duplication in a CDRI. Due to their length also these deletions/duplications may destroy the functional-
ity of the corresponding antigen receptors.
fThe data for deletions/duplications in in-frame rearrangements of memory B cells are taken from de Wildt et al. (reference 59) and the R/S values
are taken from Klein et al. and Küppers et al. (references 36 and 37). Memory B cells lack “per definition” nonsense mutations and destructive dele-
tions and duplications, as they were isolated as surface Ig  B cells.
gBesides nonfunctional rearrangements also ongoing mutations of the dominant clones of cases 4, 5, and 6 which occurred after the destructive
shared mutation in these clones are considered.
hThe data for the out-of-frame rearrangements are taken from references (references 36–38).936 Ig-deficient B Cells in Angioimmunoblastic T Cell Lymphoma
AILD acquire somatic mutations without selection for ex-
pression of a functional antigen receptor.
Considering the obvious crippling Ig mutations, the fre-
quencies of Ig-less B cells among all B cells can be calcu-
lated. In case 2,  1% of all B cells lost the capacity to ex-
press a functional antigen receptor, whereas in cases 5, 6,
and 7 the fraction of Ig-less B cells amounts to 71, 86, and
56% of all B cells, respectively. For cases 1, 2, and 4 frac-
tions of 4, 0, and 43% of Ig-less B cells among the EBER 
B cells were calculated.
Discussion
Clonal Expansion of EBV-infected B Cells in AILD. In
this study, clonal B cell expansions were detected among
the EBV-infected cells in each of the six cases of AILD-type
T cell lymphoma analyzed. The number of clones and their
sizes differed markedly between cases, ranging from small
oligoclonal to large monoclonal expansions encompassing
nearly all B cells in the infiltrated tissue. In cases 2, 8, and 9,
where large numbers of EBV , CD20  and Ki67 , prolif-
erating B cells were analyzed, no large clones were detected
among these cells (for case 6 see below). Only in case 7,
where no T cell clone was detected, nearly all EBV  B cells
belonged to a single clone, likely representing a tumor clone.
Hence it appears that most large B cell clones in EBV-posi-
tive cases of AILD represent expanding EBV-infected B cells,
pointing to a role of EBV in these expansions.
An exceptional situation was observed in case 6, where a
large B cell clone was identified which was only partially
EBV-infected (Fig. 2). The finding that EBV is restricted to
a particular branch in the somatic mutation-based genea-
logical tree of this clone may indicate that EBV infection
happened in a member of an already expanding B cell
clone. Alternatively, EBV might have been present already
in the founder cell of the clone but was later lost from a
member of the clone that then established the EBV-nega-
tive branch in the genealogical tree. Such a loss of EBV has
been described for some cases of Burkitt’s lymphoma (39).
The observed spectrum of expansions among EBV-
infected cells resembles the spectrum found in patients
with posttransplantation lymphoproliferative disease (17,
40, 41). Like in posttransplantation patients, also in AILD,
an initial polyclonal expansion of EBV-transformed B cells
in a setting of insufficient control of these cells by cyto-
toxic T cells (42) may lead to the outgrowth of a dominant
clone which perhaps acquired genetic changes conferring a
growth advantage and occasionally may give rise to a ma-
lignant B cell clone. Indeed, in AILD patients EBV  im-
munoblastic B cell lymphomas have been repeatedly ob-
served (9–11). However, whereas EBV  lymphomas in
posttransplantation lymphomas are characterized by ex-
pression of the full spectrum of latent EBV proteins (43),
the expanded cells detected in AILD do not express
EBNA2.
EBV Is Largely Restricted to Memory and GC-like B Cells in
AILD. Although there are also many naive B cells present
in the lymph node biopsies of AILD patients, as indicated
from the analysis of EBV-negative cells in cases 2, 7, 8, and
9, the vast majority of EBV-infected B cells carried mutated
Ig V genes and are thus memory or GC-like B cells. The
somatic mutation pattern of rearranged V genes of the
unique EBV  cells indicates that they are mostly memory B
cells selected for expression of a functional antigen receptor:
with three exceptions no inactivating mutations were ob-
served and the R/S ratio of 1.3 for the FRs is within the
range typical for memory B cells (1.0–1.6) and considerably
lower than the value of GC B cells (1.8; Table III). Also the
EBV-positive B cells belonging to small clones without on-
going mutation likely represent selected memory B cells, as
no inactivating mutations were observed and the R/S ratio
is 1.1 (Table III). This propensity of EBV to reside and per-
sist in long-lived memory B cells is observed also during
primary infection with EBV in infectious mononucleosis,
and in peripheral blood of healthy virus carriers (44, 45).
About half of the clones showed ongoing somatic muta-
tion in the course of clonal expansion (Table II). Since so-
matic hypermutation is regarded as a GC B cell–specific
process (46), these clones of EBV-infected B cells resemble
expanding GC B cells. Notably, some clones are composed
of members without common mutations (including clones
with unmutated members), indicating that in these cases
unmutated (naive) B cells were originally EBV-infected
and then induced to proliferate and differentiate to GC-like
cells. For clones with shared mutations and intraclonal di-
versity (like clone 3 of case 1 and clone 1 of case 4; Fig. 2),
it remains unclear whether naive, GC, or memory B cells
were originally infected by EBV.
Thus, in AILD patients EBV is mainly found in two
types of B cells: cells resembling memory B cells and show-
ing relatively little tendency for clonal expansion and cells
resembling GC B cells which are characterized by clonal
expansion and ongoing somatic mutation.
Survival and Clonal Expansion of “Forbidden” B Cells in
AILD. In the clones with ongoing somatic mutation, the
frequencies of nonsense mutations and deletions/duplica-
tions and the R/S ratios of originally potentially functional
rearrangements were in the same range as is typical for
nonfunctional out-of-frame rearrangements (Table III), in-
dicating that EBV-infected B cells with ongoing somatic
hypermutation are not selected for expression of a func-
tional antigen receptor and that for most if not all cells, se-
lection-free accumulation of mutations happened from the
beginning of the mutation activity on through many
rounds of proliferation and mutation.
Such a development of receptor-deficient B cells has not
been observed before in normal or malignant human B
cells in vivo, and is also distinct from the generation of
“crippled” HRS cells in classical HL, as discussed below.
Usually, B cells are stringently selected for expression of a
functional surface receptor throughout their life and cells
lacking an appropriate B cell receptor are efficiently and
quickly eliminated (47). Even most transformed B cells in
non-HLs still appear to depend on antigen receptor expres-
sion (48). Moreover, a sustained somatic hypermutation ac-
tivity uncoupled from control of the mutating cells by se-937 Bräuninger et al.
lection is also unprecedented in normal and malignant B
cells in vivo. These observations show that EBV infection
in the setting of AILD can have a dramatic influence on the
differentiation of B cells, allowing survival and clonal ex-
pansion of forbidden B cells.
How could EBV be involved in these processes? In
transgenic mice expressing the LMP2a gene already early in
B cell development, B lineage cells lacking a functional an-
tigen receptor are generated and survive in the periphery,
suggesting that LMP2a can mimic antigen receptor signal-
ing (49). Since LMP2a expression was observed in the
three cases with the highest content of EBER  cells (Table
I), it may be speculated, that the survival of cells with inac-
tivated antigen receptor could at least partly be due to
LMP2a expression. Moreover, LMP1, which simulates
CD40 signaling and thus functions as a survival signal for B
cells (50), was also found to be expressed by a fraction of
the EBV-harboring B cells and may thus synergize with
LMP2a in the rescue of Ig-deficient B cells.
It is likely that also the microenvironment in the AILD-
affected lymph nodes plays a role in the development of the
receptor-less B cells, because similar cells have not been
seen in other instances where EBV-infected B cells are
found and proliferate (see below). Whereas GCs are only
rarely found in AILD, large aggregates of FDCs are usually
present (7), and, together with the numerous T cells, may
provide a microenvironment inducing or maintaining so-
matic hypermutation in some cells, similar to their pro-
posed role in normal GCs. Moreover, AILD differs from
most other B cell non-HLs by the production of a variety
of cytokines in the tissue. Besides IL-6 and TNF-  also
lymphotoxin is produced (51, 52). Since the latter two cy-
tokines are known to induce B cell growth (53, 54), it may
well be that the stimulation of EBV-infected B cells by
these cytokines is involved in rescuing the crippled B cells
from apoptosis and supporting their clonal expansion.
With respect to a potential role of the microenviron-
ment in the survival of Ig-deficient B cells in AILD, it is in-
teresting to compare AILD with infectious mononucleosis.
In both diseases, EBV is largely restricted to memory and
GC-like B cells, and expanded clones of virus-infected B
cells are present (45). Moreover, IL-6, TNF- , and lym-
photoxin are also detectable in tonsils of patients affected
by infectious mononucleosis (51). However, no crippled B
cells were found among EBV-harboring cells in infectious
mononucleosis, and no ongoing mutation was observed
among members of expanded B cell clones (45). Perhaps,
the lack of an extensive FDC network and a dominant
population of T helper cells in infectious mononucleosis
prevents the survival of crippled B cells in this disease.
Moreover, whereas a state of immunodeficiency is ob-
served in AILD (42), there is an intense immune response
taking place against virus-harboring B cells in infectious
mononucleosis, thereby selecting for B cells that downreg-
ulate immunogenic EBV proteins that might be essential
for the survival of crippled B cells. Collectively, these fac-
tors likely prevent the survival of receptor-less B cells in in-
fectious mononucleosis and also in healthy virus carriers.
Although the strong association between expanding mu-
tating B cell clones with crippled V genes and the presence
of EBV in the cells points to a decisive role of the virus in
the rescue of the cells, it appears that in AILD occasionally
also EBV  crippled B cells can survive and expand. This is
shown here for a subset of the cells belonging to the large B
cell clone in case 6 and the clone in case 7. In both in-
stances these clones account for the vast majority of B cells
in the tissue, and thus likely represent B cell tumors that ac-
quired transforming events other than EBV. For the clone
of case 7 the mutation pattern may indicate that the clone
was initially dependent on a B cell receptor, as none of the
many shared mutations (20 in VH and 33 in V ) is obvi-
ously crippling. A transforming event rendering the clone
independent of a functional receptor likely occurred later
in the course of its clonal expansion, now allowing the per-
sistence of clone members with destructive mutations. The
observation of ongoing mutation in this EBV  clone is in
line with the idea that factors in the microenvironment of
AILD tissues play an important role in triggering somatic
hypermutation in expanding B cell clones (see above). The
single dominant clones of crippled B cells found in cases 4
and 5 may also have acquired additional transforming
events besides EBV infection and perhaps represent B cell
tumors developing in the setting of AILD. Such events
might render the expansion of B cell clones independent
from EBV (like in case 6?).
EBV-infected B Cells in Lymphoid Malignancies: a Virus–
Host Cell Relationship with Many Faces. The three classical
types of B cell lymphomas associated with EBV-infection,
Burkitt’s lymphoma, classical HL, and posttransplantation
lymphomas, each show a distinct and characteristic pattern
of EBV latent gene expression (16). In Burkitt’s lymphoma,
only the EBNA1 protein is expressed, which is needed for
replication of the viral genome and hence maintenance of
the virus in proliferating cells (latency I). The EBV-infected
HRS cells of HL show, besides EBNA1, also LMP1 and 2a
expression (latency II). In EBV-positive B cell lymphomas
of immunocompromised patients all nine EBV-encoded
latent proteins are expressed (latency III). The expression
pattern of EBV-encoded latent genes in AILD is most sim-
ilar to the situation in HL, since absence of EBNA2 expres-
sion and detection of LMP1-positive cells and LMP2a tran-
scripts suggests a latency II profile. However, it appears that
only a fraction of the EBV-carrying cells express LMP1.
Whether this is also true for LMP2a expression, could not
be determined because of the lack of a reliable anti-LMP2a
antibody.
Crippling mutations have also been observed in the
HRS cells of classical HL in  25% of the cases (both EBV 
and EBV ; references 22, 24, 25, 27, 28, 55–58). How-
ever, there are fundamental differences between the two
situations. The mutation pattern of the V genes in HRS
cells indicates that these cells were initially selected for anti-
gen receptor expression, then acquired unfavorable V gene
mutations (e.g., a nonsense mutation or a replacement mu-
tation resulting in reduced affinity to the immunizing anti-
gen) and were finally rescued from apoptosis by some938 Ig-deficient B Cells in Angioimmunoblastic T Cell Lymphoma
transforming event, like EBV-infection in the EBV-posi-
tive cases of HL (25). Since ongoing mutation is not ob-
served in the HRS cells in classical HL, it appears that the
somatic hypermutation machinery is switched off when the
tumor precursors entered the preapoptotic state. In con-
trast, in AILD, a population of EBV-infected B cells is
driven into proliferation, activates the hypermutation pro-
cess, and acquires somatic mutations without selection right
from the beginning. Latency II was also described for very
rare EBV-infected B cells with a GC phenotype from hu-
man tonsils (19). It is presently unclear whether these cells
undergo somatic hypermutation, and if so, whether they
would tolerate crippling mutations. Babcock et al. specu-
lated that these cells will develop along the normal differ-
entiation pathway into Ig  memory B cells (19).
Taken together, in AILD two types of EBV-infected B
cells can be discriminated. A subset of the cells likely repre-
sents virus-carrying memory B cells and thus resembles the
cells seen in healthy virus carriers and during infectious
mononucleosis. These cells show little tendency for clonal
expansion. A considerable fraction of EBV-infected B cells
is driven into massive proliferation and these cells show on-
going somatic mutation during clonal expansion without
any obvious selection for functionality of the B cell recep-
tor. Such a survival and clonal expansion of Ig-deficient B
cells represents a novel type of viral latency in the B cell
compartment. Although the factors defining this particular
form of EBV persistence are far from clear, one may specu-
late that it may be the interplay between the particular mi-
croenvironment in AILD and the viral transformation of
the cells that allows the survival of populations of forbidden
B cells. In some cases, these EBV  B cell clones may de-
velop into B cell lymphomas.
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